Current Rheumatology Reports

, Volume 4, Issue 5, pp 409–414 | Cite as

Pulmonary complications of inflammatory myopathy

  • Dana P. Ascherman
Article

Abstract

Pulmonary manifestations contribute significantly to the morbidity and mortality of the idiopathic inflammatory myopathies, ranging from intrinsic lung disease to secondary complications that include aspiration pneumonia, opportunistic infection, congestive heart failure, and hypoventilation. Newer classification schemes for interstitial lung disease have permitted closer correlation between histologic subtype and clinical outcome, while diagnostic techniques such as bronchoalveolar lavage have begun to define the cellular elements responsible for immunemediated pulmonary dysfunction. Investigators have identified several serum markers correlating with inflammatory disease activity in the lung that should enhance noninvasive monitoring of therapeutic responses to newer regimens involving agents such as cyclosporine and tacrolimus. Taken together, these advances have contributed to better understanding of the immunopathogenesis of myositis-associated interstitial lung disease that should ultimately translate into more effective treatment.

Keywords

Interstitial Lung Disease Myositis Interstitial Pneumonia Dermatomyositis Adult Respiratory Distress Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dalakas MC, Sivakumar K: The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Curr Opin Neurol 1996, 9:235–239.PubMedCrossRefGoogle Scholar
  2. 2.
    Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neruol 1990, 27:343–356.CrossRefGoogle Scholar
  3. 3.
    Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:329–334.PubMedCrossRefGoogle Scholar
  4. 4.
    Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV: Interstitial lung disease in polymyositis and dermatomyositis. Am Rev Respir Dis 1990, 141:727–733.PubMedGoogle Scholar
  5. 5.
    Grau JM, Miro O, Pedrol E, et al.: Interstitial lung disease related to dermatomyositis: comparative study in patients without lung involvement. J Rheumatol 1996, 23:1921–1926.PubMedGoogle Scholar
  6. 6.
    Hochberg MC, Feldman D, Stevens MB, et al.: Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. Arthritis Rheum 1984, 31:515–524.Google Scholar
  7. 7.
    Targoff IN, Trieu EP, Plotz PH, Miller FW: Antibodies to glycyltransfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992, 35:821–830.PubMedCrossRefGoogle Scholar
  8. 8.
    Targoff IN, Arnett FC: Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990, 88:241–251.PubMedCrossRefGoogle Scholar
  9. 9.
    Marguerie C, Bunn CC, Beynon HLC, et al.: Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. QJM 1990, 77:1019–1038.PubMedGoogle Scholar
  10. 10.
    Gibson GJ: Muscle disorders and the lungs. Ballieres Clin Rheumatol 1993, 7:135–145.CrossRefGoogle Scholar
  11. 11.
    Civita LL, Battiloro R, Celano M: Nocardia pleural empyema complicating anti-Jo1 positive polymyositis during immunoglobulin and steroid therapy. J Rheumatol 2001, 28:215–216.PubMedGoogle Scholar
  12. 12.
    Kadoya A, Okada J, Iikuni Y, Kondo H: Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/ dermatomyositis or sytstemic lupus erythematosus. J Rheumatol 1996, 23:1186–1188.PubMedGoogle Scholar
  13. 13.
    Bachelez H, Schremmer B, Cadranel J, et al.: Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med 1997, 157:1501–1503.PubMedCrossRefGoogle Scholar
  14. 14.
    Targoff IN, Johnson AE, Miller FW: Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990, 33:1361–1370.PubMedCrossRefGoogle Scholar
  15. 15.
    Bunch TW, Tancredi RG, Lie JT: Pulmonary hypertension in polymyositis. Chest 1981, 79:105–107.PubMedGoogle Scholar
  16. 16.
    Santiago MB, Chalhoub M, Pereira ST: Amyopathic dermatomyositis complicated by interstitial pulmonary disease and pneumomediastinum. J Rheumatol 1998, 25:2042–2043.PubMedGoogle Scholar
  17. 17.
    Jansen T, Barrera P, van Engelen BGM, et al.: Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and review of the literature. Clin Exp Rheumatol 1198, 16:733–735.Google Scholar
  18. 18.
    Korkmaz C, Ozkan R, Akay M, Hakan T: Pneumomediastinum and subcutaneous emphysema associated with dermatomyositis. Rheumatology 2001, 40:476–478.PubMedCrossRefGoogle Scholar
  19. 19.
    Yamanishi Y, Maeda H, Konishi F, et al.: Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. Scand J Rheumatol 1999, 28:58–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Kono H, Inokuma S, Nakayama H, Suzuki M: Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000, 59:372–376. Concise comparison of clinical features in patients with myositis and with and without pneumomediastinum, including review of previously reported cases. Authors associate the cutaneous vasculopathy of dermatomyositis with the development of pneumomediastinum and therefore provide insight to possible vascular etiology of this pulmonary complication.PubMedCrossRefGoogle Scholar
  21. 21.
    Braun NM, Arora NS, Rochester DF: Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983, 38:616–623.PubMedCrossRefGoogle Scholar
  22. 22.
    Friedman AW, Targoff IN, Arnett FC: Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Sem Arth Rheum 1996, 26:459–467.CrossRefGoogle Scholar
  23. 23.
    Nishikai M, Reichlin M: Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-1 antibody system. Arthritis Rheum 1980, 23:881–888.PubMedCrossRefGoogle Scholar
  24. 24.
    Sauty A, Rochat T, Schoch OD, et al.: Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997, 10:2907–2912.PubMedCrossRefGoogle Scholar
  25. 25.
    Schwarz MI: The lung in polymyositis. Clin Chest Med 1998, 19:701–712.PubMedCrossRefGoogle Scholar
  26. 26.
    Fata F, Rathore R, Schiff C, Herzlich BC: Bronchiolitis obliterans organizing pneumonia as the first manifestation of polymyositis. South Med J 1997, 90:227–230.PubMedGoogle Scholar
  27. 27.
    Arsura EL, Grenberg AS: Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Sem Arth Rheum 1988, 18:29–37.CrossRefGoogle Scholar
  28. 28.
    Dalakas MC: Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991, 325:1487–1498.PubMedCrossRefGoogle Scholar
  29. 29.
    Ito M, Kaise S, Suzuki S, et al.: Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 1999, 18:462–467.PubMedCrossRefGoogle Scholar
  30. 30.
    Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositisspecific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360–374.PubMedCrossRefGoogle Scholar
  31. 31.
    Douglas WW, Tazelaar HD, Hartman TE, et al.: Polymyositisdermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 2002, 164:1182–1185. Based on a large cohort of patients with myositis from the Mayo Clinic, this report presents a comprehensive analysis of clinical, laboratory, radiographic, and histopathologic features characterizing patients with myositis and interstitial lung disease.Google Scholar
  32. 32.
    Schwarz MI, Sutarik JM, Nick JA, et al.: Pulmonary capillaritis and diffuse alveolar hemorrhage. Am J Respir Crit Care Med 1995, 151:2037–2040.PubMedGoogle Scholar
  33. 33.
    Clawson K, Oddis CV: Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995, 38:1519–1523.PubMedCrossRefGoogle Scholar
  34. 34.
    Travis WD, Matsui K, Moss J, Ferrans VJ: Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns. Am J Surg Pathol 2000, 24:19–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Yamadori I, Fujita J, Kajitani H, et al.: Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol Int 2001, 21:89–93. Excellent histopathologic characterization of lymphocyte subsets infiltrating lung biopsy specimens derived from patients with myositis and non-specific interstitial pneumonia.PubMedCrossRefGoogle Scholar
  36. 36.
    Akira M, Hara H, Sakatain M: Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology 1999, 210:333–338.PubMedGoogle Scholar
  37. 37.
    Ikezoe J, Johkoh T, Kohno N, et al.: High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. J Thoracic Imaging 1996, 11:250–259.CrossRefGoogle Scholar
  38. 38.
    Mino M, Noma S, Taguchi Y, et al.: Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997, 169:83–87.PubMedGoogle Scholar
  39. 39.
    Komocsi A, Kumanovics G, Zibotics H, Czirjak L: Alveolitis may persist during treatment that sufficiently controls muscle inflammation in myositis. Rheumatol Int 2001, 20:113–118.PubMedCrossRefGoogle Scholar
  40. 40.
    Kourakata H, Takada T, Suzuki E, et al.: Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/ dermatomyositis with interstitial pneumonia. Respirology 1999, 4:223–228. This study employs flourescence-activated cell sorting analysis to phenotype T cells obtained from bronchoalveolar lavage fluid of patients with myositis and interstitial lung disease. Although only eight patients with polymyositis or dermatomyositis were included, the authors found no difference in the bronchoalveolar lavage fluid distribution of T cell subsets between these two forms of inflammatory myopathy. Because this finding contrasts with the divergent cell types infiltrating muscle in polymyositis and dermatomyositis, the authors speculate that the inflammatory process affecting the lungs in interstitial lung disease differs from that of muscle and skin.PubMedCrossRefGoogle Scholar
  41. 41.
    D’Cruz D, Keser G, Khamashta MA, et al.: Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. J Rheumatol 2000, 27:161–164.PubMedGoogle Scholar
  42. 42.
    Fujita J, Dobashi N, Tokuda M, et al.: Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/dermatomyositis. J Rheumatol 1999, 26:2377–2382.PubMedGoogle Scholar
  43. 43.
    Bandoh S, Fujita J, Ohtsuki Y, et al.: Sequential changes of KL- 6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 2000, 59:257–262. Through longitudinal analysis, this study nicely demonstrates the correlation between serum levels of KL-6 and activity of interstitial lung disease.PubMedCrossRefGoogle Scholar
  44. 44.
    Schnabel A, Reuter M, Gross W: Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998, 41:1215–1220.PubMedCrossRefGoogle Scholar
  45. 45.
    Maeda K, Kimura R, Komuta K, Igarashi T: Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997, 26:24–29.PubMedCrossRefGoogle Scholar
  46. 46.
    Nawata Y, Kurasawa K, Takabayashi K, et al.: Corticosteroid resistant interstitial pneumonia in dermatomyositis/ polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999, 26:1527–1533. This retrospective study demonstrated the effectiveness of low-dose cyclosporine in five patients with myositis and interstitial lung disease refractory to therapy with corticosteroids.PubMedGoogle Scholar
  47. 47.
    Oddis CV, Sciurba FC, Elmagd KA, Starzl TE: Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353:1762–1763. This report represents the first published case series of patients treated with tacrolimus for refractory myositis complicated by interstitial lung disease, demonstrating efficacy in four out of five patients.PubMedCrossRefGoogle Scholar
  48. 48.
    Bingham S, Griffiths B, McGonagle D, et al.: Autologous stem cell transplantation for rapidly progressive Jo-1-positive polymyositis and long-term follow-up. Br J Haematol 2001, 113:840–841.PubMedCrossRefGoogle Scholar
  49. 49.
    Baron F, Ribbens C, Kaye O, et al.: Effective treatment of Jo-1- associated polymyositis with T-cell-depleted auologous peripheral blood stem cell transplantation. Br J Haematol 2000, 110:339–342.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Dana P. Ascherman
    • 1
  1. 1.Division of Rheumatology and Clinical ImmunologyUniversity of PittsburghPittsburghUSA

Personalised recommendations